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Abstract
Background Advances in HIV-1 therapeutics have led to the development of a range of daily oral treatment regimens, 
which share similar high efficacy rates. Consequently, more emphasis is being placed upon the individual’s experience of 
treatment and impact on quality of life. The first long-acting injectable antiretroviral therapy for HIV-1 (long-acting cabo-
tegravir + rilpivirine [CAB + RPV LA]) may address challenges associated with oral treatment for HIV-1, such as stigma, 
pill burden/fatigue, drug–food interactions, and adherence. Patient-reported outcomes (PROs) collected in an HIV-1 clinical 
trial (ATLAS-2M; NCT03299049) comparing participants’ experience with two dosing regimens (every 4 weeks [Q4W] vs. 
every 8 weeks [Q8W]) of CAB + RPV LA are presented herein.
Methods PRO endpoints evaluated through 48 weeks of therapy included treatment satisfaction (HIV Treatment Satisfac-
tion Questionnaire [HIVTSQ]), treatment acceptance (“General Acceptance” domain of the Chronic Treatment Acceptance 
 [ACCEPT®] questionnaire), acceptability of injections (Perception of Injection [PIN] questionnaire), treatment preference 
(questionnaire), and reasons for switching to/continuing long-acting therapy (exploratory endpoint; questionnaire). Partici-
pants were randomized 1:1 to receive CAB + RPV LA Q8W or Q4W. Results were stratified by prior CAB + RPV exposure 
in either preplanned or post hoc analyses.
Results Overall, 1045 participants were randomized to the Q8W (n = 522) and Q4W (n = 523) regimens; 37% (n = 391/1045) 
had previously received CAB + RPV in ATLAS. For participants without prior CAB + RPV exposure, large increases from 
baseline were reported in treatment satisfaction in both long-acting arms (HIVTSQ status version), with Q8W dosing sta-
tistically significantly favored at Weeks 24 (p = 0.036) and 48 (p = 0.004). Additionally, improvements from baseline were 
also observed in the “General Acceptance” domain of the ACCEPT questionnaire in both long-acting arms for participants 
without prior CAB + RPV exposure; however, no statistically significant difference was observed between arms at either 
timepoint (Week 24, p = 0.379; Week 48, p = 0.525). Significant improvements (p < 0.001) in the “Acceptance of Injection Site 
Reactions” domain of the PIN questionnaire were observed from Week 8 to Weeks 24 and 48 in both arms for participants 
without prior CAB + RPV exposure. Participants with prior CAB + RPV exposure reported high treatment satisfaction (mean 
[HIVTSQ status version]: Q8W 62.2/66.0; Q4W 62.0/66.0), treatment acceptance (mean: Q8W 89.3/100; Q4W 91.2/100), 
and acceptance of injection site reactions (mean [5 = not at all acceptable; 1 = totally acceptable]: Q8W 1.72; Q4W 1.59) at 
baseline/Week 8 that were maintained over time. Participants without prior CAB + RPV exposure who received Q8W dosing 
preferred this regimen over oral CAB + RPV (98%, n = 300/306). Among those with prior Q4W exposure, 94% (n = 179/191) 
preferred Q8W dosing versus Q4W dosing (3%, n = 6/191) or oral CAB + RPV (2%, n = 4/191).
Conclusions Both long-acting regimens provided high treatment satisfaction and acceptance, irrespective of prior CAB + RPV 
exposure, with most participants preferring Q8W dosing over both the Q4W regimen and their previous daily oral regimen. 
The PRO data collected at Week 48 support the therapeutic potential of CAB + RPV LA.
Funding ViiV Healthcare and Janssen.
Trial Registration ATLAS-2M: ClinicalTrials.gov NCT03299049, registered October 2, 2017.
Extended author information available on the last page of the article
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Plain Language Summary
Developments in HIV-1 treatment have resulted in effective daily oral medications. However, life-long pill taking can come 
with several challenges. These include having a daily reminder of living with HIV-1. Treatment satisfaction is important to 
consider when evaluating a new medicine. This is because it can affect people’s quality of life. The purpose of this study 
was to evaluate people’s experiences with the first long-acting injectable medicine for HIV-1. The medicine is called cabo-
tegravir + rilpivirine long-acting (CAB + RPV LA). Over approximately 1 year, this study measured people’s satisfaction 
and experiences while receiving injections of CAB + RPV LA. Injections were given either every 4 weeks or every 8 weeks. 
The study included people who had never had CAB + RPV LA, as well as people who were already receiving CAB + RPV 
LA. For people new to CAB + RPV LA, their satisfaction increased compared with their previous medication. They also had 
improvements in their experiences of injection site reactions throughout the study. For people who were already receiving 
CAB + RPV LA, their high satisfaction with this treatment and tolerability of injection site reactions were maintained over 
time. Overall, improvements were similar between people receiving injections every 4 weeks and people receiving injections 
every 8 weeks. People with experience of both injection schedules tended to prefer to receive injections every 8 weeks. These 
results show that CAB + RPV LA can provide quality-of-life improvements for people who have HIV-1.
Key Points for Decision Makers 
Participants with no previous experience with  
cabotegravir + rilpivirine (CAB + RPV) reported 
increases in treatment satisfaction for both the every 
8 weeks regimen and every 4 weeks regimen over their 
previous daily oral regimen.
Participants were found to be satisfied with CAB + RPV 
long-acting (LA) as a treatment for the maintenance of 
virologic suppression across a range of patient-reported 
outcomes.
For participants with exposure to both dosing regimens 
of CAB + RPV LA, most participants preferred the every 
8 weeks regimen over the every 4 weeks regimen.
1 Introduction
Advances in the efficacy of antiretroviral therapy [1] have 
led to a shift in treatment focus to emphasize convenience, 
tolerability, and overall acceptability of HIV therapy [2]. 
This has culminated in the development of efficacious sin-
gle-tablet daily oral regimens, which offer simplicity and 
convenience [3]. Despite this, the need for life-long daily 
pill-taking can present substantial challenges that can be 
broadly grouped into three categories: adherence issues [4]; 
emotional issues, including stigmatization concerns and the 
daily reminder of HIV status [5]; and medical issues, such 
as difficulty swallowing, drug–food and drug–drug inter-
actions, and pill burden [6]. These challenges can impact 
the likelihood of treatment failure, with poor adherence to 
antiretroviral therapy linked to the emergence of resistance 
and virologic failure [7–10]. Consequently, there is consid-
erable interest across a range of patient demographics in 
long-acting therapies, in particular, injectable long-acting 
therapies, which may help to alleviate some of the chal-
lenges associated with daily oral therapy [11–15].
Cabotegravir (CAB), an HIV integrase strand transfer 
inhibitor, and rilpivirine (RPV), a non–nucleoside reverse 
transcriptase inhibitor, are the first intramuscular long-acting 
antiretroviral regimen (CAB + RPV LA) for the maintenance 
of virologic suppression in people living with HIV-1 and 
can be dosed monthly or every 2 months [16–18]. Currently, 
CAB + RPV LA is approved for use in Australia, the USA, 
Canada, and the European Union for adults with HIV-1. 
Both CAB and RPV are also available as separate once-
daily oral tablets, intended for use as an oral lead-in to assess 
safety and tolerability prior to initiation of the long-acting 
regimen. These tablets can also be used as a bridge for the 
long-acting regimen if there are planned interruptions to 
treatment [16–18].
The phase 2b LATTE-2 study (NCT02120352) demon-
strated that CAB + RPV LA dosed every 4 weeks (Q4W) or 
every 8 weeks (Q8W) was as effective as continuing oral 
CAB + abacavir/lamivudine for maintaining virologic sup-
pression [19]. Qualitative interviews with 39 participants 
revealed that the long-acting regimen was perceived as a 
highly acceptable and desirable alternative to oral therapy, 
with convenience and peace of mind reported as the primary 
contributing factors [20]. CAB + RPV LA has also been 
evaluated in three phase 3 studies. ATLAS (NCT02951052) 
and FLAIR (NCT02938520), both individually [16, 17] and 
in a pooled analysis [21], demonstrated the noninferiority 
of CAB + RPV LA Q4W for the maintenance of virologic 
suppression versus continuing daily oral therapy. Moreo-
ver, a pooled analysis of patient-reported outcomes (PROs) 
from these two studies found high levels of participant sat-
isfaction, acceptance, and tolerability with CAB + RPV 
LA, with most participants preferring the long-acting regi-
men to oral therapy [22]. Subsequently, the ATLAS-2M 
(NCT03299049) study demonstrated the noninferiority of 
CAB + RPV LA Q8W versus Q4W dosing for the mainte-
nance of virologic suppression [18].
Patient-Reported Outcomes Through 1 Year of ATLAS-2M
Increased patient satisfaction has been shown to improve 
adherence [23], which contributes to the maintenance of 
long-term HIV suppression as well as preventing drug resist-
ance, slowing disease progression, and reducing mortality 
[9, 10, 24–26]. PROs can aid treatment optimization as they 
provide key insights into quality-of-life issues that have 
the potential to influence adherence to life-long treatment. 
Previous clinical trials have demonstrated that participants 
switching between contemporary oral antiretroviral regi-
mens experience modest improvements in PROs [27–29]. 
Here, we evaluate and compare participants’ experience with 
the two dosing regimens of CAB + RPV LA (Q4W vs. Q8W) 
using PRO data from preplanned and post hoc analyses in 
ATLAS-2M.
2  Methods
2.1  Study Design and Participants
ATLAS-2M (electronic supplementary material Figure S1) 
is an ongoing, multicenter, phase 3b, randomized, open-label 
study investigating whether CAB + RPV LA Q8W is nonin-
ferior to CAB + RPV LA Q4W. The eligibility criteria, study 
design, and methodology for participant recruitment have 
been reported previously in the primary clinical manuscript 
[18]. Briefly, eligible participants were adults (≥ 18 years) 
with antiretroviral therapy experience, virologic suppression 
(HIV-1 RNA < 50 copies/mL), and no history of resistance. 
Participants from either the standard of care or CAB + RPV 
LA (Q4W) arms of the ATLAS study (NCT02951052) 
were also eligible to enter ATLAS-2M, provided they had 
received treatment through a minimum of 52 weeks in the 
ATLAS study and were virologically suppressed at ATLAS-
2M screening.
After screening, participants were randomized 1:1 to 
receive CAB + RPV LA in the maintenance phase, dosed 
either Q8W (CAB 600 mg + RPV 900 mg) or Q4W (CAB 
400 mg + RPV 600 mg). Randomization was stratified by 
three categories of prior CAB + RPV (oral + intramuscular) 
exposure (0, 1–24, and > 24 weeks) to account for those indi-
viduals entering from the ATLAS study and the difference 
in treatments assessed at baseline (participants transitioning 
from the randomized Q4W arm in ATLAS had > 24 weeks 
of exposure to CAB + RPV, whereas all but one participant 
transitioning from the randomized standard of care arm 
had < 24 weeks of exposure to CAB + RPV whilst wait-
ing for enrollment into ATLAS-2M [one participant had 
24–48 weeks of exposure]). ATLAS-2M was conducted 
in accordance with the principles founded in the Declara-
tion of Helsinki [30] and with Good Clinical Practice [31]. 
All participants provided written informed consent, and the 
protocol was approved by an institutional review board or 
ethics committee.
2.2  Assessments and Endpoints
Several PRO instruments (Table 1) were included at pre-
specified timepoints in the ATLAS-2M study to assess toler-
ability and acceptability of injections, treatment satisfaction, 
acceptance, and preference. The PRO instruments utilized 
are detailed below alongside references to studies validating 
their psychometric properties.
2.2.1  Perception of Injection (PIN) Questionnaire
The acceptability and tolerability of injections and injec-
tion site reactions (ISRs) was assessed using the Perception 
of Injection (PIN) questionnaire. The PIN questionnaire 
was modified for gluteal intramuscular injection from the 
Vaccinees’ Perception of Injection (VAPI) questionnaire, 
developed and validated to assess perception and accept-
ance of influenza vaccination [32]. A validation publication 
assessing its use in an HIV population is under preparation. 
The questionnaire comprises 21 items across four dimen-
sions taken from the VAPI, “Acceptance of ISRs,” “Bother 
of ISRs,” “Sleep,” and “Leg movement,” and five new indi-
vidually reported items related to willingness to receive an 
HIV injectable treatment at the following visit, pain during 
injection, satisfaction with the mode of treatment adminis-
tration, and anxiety before and after the injection. Answers 
to the questionnaire are reported as scores ranging from 
1 to 5, representing, in order, “totally acceptable,” “very 
acceptable,” “moderately acceptable,” “a little acceptable,” 
and “not at all acceptable.” The mean of all items within 
a dimension was taken to give the score of the dimension. 
Only the “Acceptance of ISRs” domain was included in this 
analysis and remained unchanged from the original version.
2.2.2  Chronic Treatment Acceptance Questionnaire 
 (ACCEPT®)
How participants weigh the advantages and disadvantages 
of long-term medications was assessed using the “General 
Acceptance” domain of the Chronic Treatment Acceptance 
(ACCEPT) questionnaire, validated in populations receiving 
treatment for a chronic disease (including HIV-1) [33, 34]. 
The domain consists of the following three items:
1. ‘Do you agree with the following statement: “My medi-
cation has more advantages than disadvantages”?’
2. “Given the advantages and disadvantages of your medi-
cation, do you consider it to be an acceptable solution?”
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3. “Are you convinced that in the long term, it is worth 
taking your medications?”
Participant responses are rated on a 5-point Likert scale, 
with 5 representing “I don’t know” and scores of 1 through 
4 representing increments in agreement or acceptance from 
“totally disagree/not at all acceptable/not at all convinced” 
through to “totally agree/totally acceptable/totally con-
vinced.” An aggregate score was then produced from the 
individual item scores and linearly transformed to range 
from 0 to 100, with higher scores representing greater agree-
ment or acceptance.
2.2.3  HIV Treatment Satisfaction Questionnaire (Status 
and Change Versions)
Treatment satisfaction was assessed using a 12-item ques-
tionnaire adapted from the original 10-item HIV Treatment 
Satisfaction Questionnaire (HIVTSQ), which was validated 
in a population with HIV-1 [35]. The 12-item adaptation was 
previously used in the ATLAS [17] and FLAIR [16] studies 
and validated in the LATTE-2 study [19] (publication pend-
ing). The two additional items were added to specifically 
address the mode of administration of CAB + RPV LA (i.e., 
injectable intramuscular dosing). These were:
1. “How easy or difficult have you been finding your treat-
ment to be recently?”
2. “How satisfied are you with the amount of discomfort 
or pain involved with your present form of treatment?”
HIVTSQ status version (HIVTSQs) instructs participants 
to rank their answers on a 6-point Likert scale (ranging from 
6 [“very satisfied”] to 0 [“very dissatisfied”]). In contrast, 
HIVTSQ change version (HIVTSQc) asks participants to 
compare the HIV therapy they were receiving prior to enter-
ing ATLAS-2M with their current treatment and rank their 
answers from 3 (“much more satisfied now”) to − 3 (“much 
less satisfied now”). HIVTSQc can help to account for the 
potentially high baseline values recorded with HIVTSQs and 
prevent measurement limitations (ceiling effects), which can 
be associated with satisfaction measurements and mask the 
magnitude of treatment effects (maximum or near-maximum 
satisfaction at baseline resulting in recording little or no 
improvement at later timepoints) [36, 37]. In both versions, 
item scores were added together to give a total aggregate 
summary score (HIVTSQs: 0 [minimum, very dissatisfied], 
Table 1  ATLAS-2M PRO instruments
ACCEPT Chronic Treatment Acceptance Questionnaire, CAB cabotegravir, ISR injection site reaction, HAT-QoL HIV/AIDS-targeted quality of 
life, HIVTSQs/c HIV Treatment Satisfaction Questionnaire (status version)/(change version), LA long-acting, PIN Perception of Injection, PRO 
patient-reported outcome, Q4W every 4 weeks, RPV rilpivirine, SoC standard of care
a Analyses stratified by prior CAB + RPV exposure were post hoc
b Prespecified analysis was stratified by prior regimen (randomized CAB + RPV LA Q4W in ATLAS vs. SoC [randomized to SoC in ATLAS/
receiving SoC in routine clinic])
c Data not shown. The results remained generally stable across all visits, irrespective of prior CAB + RPV exposure, with no significant changes 
from baseline after adjusting for prespecified covariates
PRO instrument Assessment Timepoints measured Stratified by prior
CAB + RPV exposure 
(prespecified analysis)
Endpoint
PIN questionnaire Perception of pain and ISRs Week 8, Week 24, Week 48 (or 
withdrawal)
Noa Secondary
ACCEPT Patient acceptance of treatment Baseline, Week 24, Week 48 (or 
withdrawal)
Yes Secondary
HIVTSQs Patient satisfaction with HIV  
treatment
Baseline, Week 24, Week 48 (or 
withdrawal)
Yes Secondary
HIVTSQc Change in patient satisfaction with 
HIV treatment from previous 
regimen
Week 48 (or withdrawal) Noa,b Secondary
Preference for HIV Treatment Patient preference for CAB + RPV 
LA vs. oral CAB + RPV and 
reasons for preference
Week 48 (or withdrawal) Yes Secondary
HAT-QoLc Patient life satisfaction, disclosure 
worries, and HIV medication





Patient reasoning for switching to 
LA therapy from oral therapy/ 
continuing LA therapy
Baseline Nob Exploratory
Patient-Reported Outcomes Through 1 Year of ATLAS-2M
66 [maximum, very satisfied]; HIVTSQc: − 33 [minimum, 
much less satisfied now], 33 [maximum, much more satis-
fied now]).
2.2.4  Preference
To assess participant preference, a single-item question eval-
uating treatment preference, along with questions evaluat-
ing attributes supporting this preference, was included. The 
question read:
1. “Based on your experience, which HIV treatment do you 
prefer?”
The single-item question had multiple closed-format 
response options. For participants without prior CAB + RPV 
exposure, response options were between the Q8W or Q4W 
regimen they received in ATLAS-2M and their previous 
daily oral regimen. For those with prior CAB + RPV expo-
sure in the Q8W arm, response options were between the 
Q8W regimen, the Q4W regimen (received previously in 
ATLAS), and their previous daily oral regimen. For those 
with prior exposure in the Q4W arm, only Q4W dosing and 
daily oral dosing were response options.
2.2.5  Reason for Switch
To explore the reasons why participants elected to switch 
to or continue long-acting treatment, a single-item question 
was administered. The question read:
1. “You have chosen to participate in a clinical study where 
your daily oral HIV medication will be switched to a 
long-acting injectable HIV medication. What are the 
main reasons for your willingness to switch to a long-
acting injectable HIV medication from your current oral 
HIV medication?”
Or
2. “You have chosen to participate in a clinical study where 
you will continue to receive long-acting injectable HIV 
medication. What are the main reasons for your will-
ingness to continue with a long-acting injectable HIV 
medication?”
The multiple closed-format response options are shown 
in electronic supplementary material Figure S2.
2.3  Statistical Analysis
Descriptive statistics were used to summarize question-
naire scores for each visit (baseline, Week 8, Week 24, 
and Week 48). The prespecified analysis of ACCEPT 
and HIVTSQs was stratified by prior CAB + RPV expo-
sure (0 weeks vs. ≥ 1 week of exposure) to account for 
the different treatments assessed at baseline. A post hoc 
analysis of PIN and HIVTSQc was also stratified by prior 
CAB + RPV exposure (0 weeks vs. ≥ 1 week of exposure). 
An analysis of covariance (ANCOVA) model was used to 
examine treatment differences at each visit for HIVTSQs, 
ACCEPT, and PIN, and was adjusted for select covari-
ates. For HIVTSQs and ACCEPT, these included baseline 
score, sex at birth (female, male), age (< 50, ≥ 50 years), 
and race (white, non-white). For the post hoc analysis 
of PIN, treatment differences were adjusted for Week 8 
score, sex at birth (female, male), age (< 50, ≥ 50 years), 
and race (white, non-white). An ANOVA model was 
used to assess treatment differences at Week 48 for 
HIVTSQc and was adjusted for sex at birth (female, 
male), age (< 50, ≥ 50 years), and race (white, non-white). 
These models were also adjusted for prior exposure to 
CAB + RPV (1–24, > 24 weeks) when examining non-
naive participants to CAB + RPV. The prespecified analy-
sis of treatment differences for PIN was adjusted for Week 
8 score, sex at birth (female, male), age (< 50, ≥ 50 years), 
race (white, non-white), and prior exposure to CAB + RPV 
(0, 1–24, > 24 weeks). P values and 95% confidence inter-
vals (CIs) for the treatment differences between groups are 
reported. Change in PIN acceptance score from Week 8 to 
Week 24 and Week 48 were evaluated for each treatment 
group using a Wilcoxon signed-rank test. Missing data 
were imputed using a last-observation-carried-forward 
approach including measures assessed at time of with-
drawal. For the preference questionnaire, the prespecified 
analysis was the respondent’s analysis (participants that 
responded at Week 48 or withdrawal). For the exploratory 
endpoint (reason for switch), proportions are reported for 
observed cases without imputation, statistical modeling, 
or testing. A statistical appendix can be found in the elec-
tronic supplementary material. 
3  Results
3.1  Baseline Characteristics
The intention-to-treat exposed population consisted of 
1045 participants (Q8W, n = 522; Q4W, n = 523). Base-
line characteristics have been reported previously and 
were similar between dosing arms [18]. Overall, 37% 
(n = 391/1045) of participants entered ATLAS-2M with 
prior CAB + RPV experience in ATLAS, most of whom 
(65%, n = 253/391) had > 48 weeks of prior exposure.
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3.2  Acceptability of ISRs (PIN Questionnaire)
At Week 8, most participants reported their acceptance 
of pain (Q8W 67%; Q4W 69%) and local reactions (Q8W 
81%; Q4W 82%) as either “totally acceptable” or “very 
acceptable” (“Acceptance of ISRs” domain of the PIN 
questionnaire) (Fig. 1a, b). Across both long-acting groups, 
a statistically significant improvement (p < 0.005) in the 
acceptability of ISRs was observed from Week 8 to Weeks 
24 and 48 (Fig. 2a), with 77% of participants in either treat-
ment arm (Q8W, n = 399/515; Q4W, n = 398/515) rating 
pain as “totally acceptable” or “very acceptable” at Week 48 
(Fig. 1b). Further, 85% (n = 439/515) and 84% (n = 434/515) 
of participants rated their local reactions as “totally accept-
able” or “very acceptable” at Week 48 in the Q8W and Q4W 
arms, respectively (Fig. 1a). No statistically significant dif-
ference in adjusted mean change from Week 8 to Weeks 
24 and 48 in acceptability of ISRs was observed between 
the long-acting groups (Week 24 adjusted difference 
[Q8W − Q4W] [95% CI] 0.01 [− 0.07 to 0.10], p = 0.768; 
Week 48 adjusted difference [Q8W − Q4W] [95% CI] −0.04 
[− 0.13 to 0.05], p = 0.391). 
When stratified by prior CAB + RPV exposure, statisti-
cally significant improvements (p < 0.001) from Week 8 to 
Weeks 24 and 48 in the acceptability of ISRs were observed 
for participants with no prior exposure across both long-
acting groups (Fig. 2b). For participants with prior exposure, 
representing participants transitioning from the ATLAS 
study, mean (standard deviation [SD]) acceptability of ISRs 
was high at Week 8 (Q8W 1.72 [0.842]; Q4W 1.59 [0.741]) 
and was maintained through Weeks 24 (Q8W 1.76 [0.805]; 
Q4W 1.67 [0.740]) and 48 (Q8W 1.68 [0.840]; Q4W 1.65 
[0.779]) in both long-acting groups.
3.3  Treatment Acceptance (“General Acceptance” 
Domain of ACCEPT)
For participants without prior exposure to CAB + RPV, 
baseline scores in the “General Acceptance” domain of the 
ACCEPT questionnaire, evaluating participants’ accept-
ance of prior daily oral therapy, were similar between both 
long-acting groups (mean [SD]: Q8W 81.5/100 [25.23]; 
Q4W 81.8/100 [25.98]). At Week 24 and Week 48, marked 
improvements from baseline in treatment acceptance were 
observed across both long-acting groups (adjusted mean 
change from baseline [95% CI] [percentage change from 
baseline, calculated as the adjusted mean change from 
baseline divided by the mean baseline score multiplied 
by 100]: Q8W: Week 24, 5.8 [3.2–8.5] [+ 7%]; Week 
48, 6.8 [4.3–9.3] [+ 8%]; Q4W: Week 24, 4.2 [1.5–6.8] 
[+ 5%]; Week 48, 5.7 [3.2–8.1] [+ 7%]) (Fig. 3a). As per 
the preplanned statistical analysis, no significant differ-
ences were observed between the two long-acting groups 
in change from baseline in treatment acceptance at Weeks 
24 (p = 0.379) and 48 (p = 0.525).
For participants with prior CAB + RPV exposure, base-
line “General Acceptance” scores, evaluating participants’ 
acceptance of prior Q4W long-acting therapy, were high 
and similar across long-acting groups (mean baseline 
[SD]: Q8W 89.3/100 [20.03]; Q4W 91.2/100 [16.74]). 
Scores remained high at Weeks 24 and 48 without signifi-
cant differences between treatment groups (Fig. 3b). For 
most of these participants (65%, n = 253/391), this repre-
sented ~ 96 weeks of cumulative experience of long-acting 





































































































































How acceptable was your pain?
a b
CAB+RPV LA Q8W CAB+RPV LA Q4W
Fig. 1  “Acceptance of ISRs” domain of the PIN questionnaire 
through Week  48a. CAB cabotegravir, ISR injection site reaction, 
LA long-acting, PIN Perception of Injection, Q4W every 4  weeks, 
Q8W every 8 weeks, RPV rilpivirine. aWeek 8: Q8W, n = 514; Q4W, 
n = 515; Week 24: Q8W, n = 515; Q4W, n = 515; Week 48: Q8W, 
n = 515; Q4W, n = 515
Patient-Reported Outcomes Through 1 Year of ATLAS-2M
3.4  Treatment Satisfaction (HIVTSQs/c)
For participants without prior CAB + RPV exposure, base-
line HIVTSQs mean (SD) scores were similar between treat-
ment groups (Q8W 57.73/66.00 [9.21]; Q4W 56.72/66.00 
[9.34]). At both Week 24 and Week 48, HIVTSQs total 
scores were markedly improved from baseline (adjusted 
mean change from baseline [95% CI] [percentage change 
from baseline, calculated as the adjusted mean change from 
baseline divided by the mean baseline score multiplied by 
100]: Q8W: Week 24, 5.07 [4.36–5.78] [+ 9%]; Week 48, 
4.86 [4.02–5.69] [+ 8%]; Q4W: Week 24, 4.00 [3.29–4.70] 
[+ 7%]; Week 48, 3.12 [2.29–3.95] [+ 6%]) (Fig. 4a), with 
statistically significant differences in the adjusted mean 
change from baseline favoring Q8W dosing at both time-
points (Week 24, p = 0.036; Week 48, p = 0.004). At Week 
48, treatment satisfaction had improved from baseline in 
nine of the 12 individual items, with Q8W dosing scoring 
equal to or higher than the Q4W dosing arm in all nine items 
(electronic supplementary material Figure S3).
For participants with prior CAB + RPV exposure, 
HIVTSQs mean (SD) scores were high at baseline (Q8W 
62.22/66.00 [5.41]; Q4W 61.98/66.00 [6.72]) and remained 
stable from Week 24 to Week 48 (Fig. 4b). By Week 48 of 
ATLAS-2M, most of these participants (65%, n = 253/391) 
who had transitioned from the ATLAS study had ~ 96 weeks 
of cumulative experience of long-acting therapy. No sig-
nificant differences (p > 0.05) in HIVTSQs were found 
between the long-acting groups at any timepoint. At Week 
48, HIVTSQc scores, used to account for ceiling effects 
[37], showed an improvement in treatment satisfaction com-








































































































CAB+RPV LA Q8W CAB+RPV LA Q4W
Fig. 2  Mean “Acceptance of ISRs” domain of the PIN questionnaire 
score through Week 48 for the total  populationa (a) and participants 
with no prior CAB + RPV  exposureb (b). CAB cabotegravir, ISR 
injection site reaction, LA long-acting, PIN Perception of Injec-
tion, Q4W every 4 weeks, Q8W every 8 weeks, RPV rilpivirine, SD 
standard deviation. aWeek 8: Q8W, n = 514; Q4W, n = 515; Week 24: 
Q8W, n = 515; Q4W, n = 515; Week 48: Q8W, n = 515; Q4W, n = 515. 
P values correspond to the Wilcoxon signed-rank test used to com-
pare the Week 24 and Week 48 scores with the Week 8 scores. P 
values are derived for “acceptance” only and not adjusted for multi-
ple testing. bWeek 8: Q8W, n = 320; Q4W, n = 321; Week 24: Q8W, 
n = 321; Q4W, n = 321; Week 48: Q8W, n = 321; Q4W, n = 321. P 
values correspond to the Wilcoxon signed-rank test used to compare 
the Week 24 and Week 48 scores with the Week 8 scores. P values 
are derived for “acceptance” only and not adjusted for multiple test-
ing
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CAB+RPV LA Q8W CAB+RPV LA Q4W
Fig. 3  Adjusted mean change from baseline in “General Acceptance” 
score of the ACCEPT questionnaire by visit for participants without 
prior CAB + RPV exposure (a) and with prior CAB + RPV expo-
sure (b)a. ACCEPT Chronic Treatment Acceptance Questionnaire, 
ANCOVA analysis of covariance, CAB cabotegravir, CI confidence 
interval, LA long-acting, Q4W every 4 weeks, Q8W every 8 weeks, 
RPV rilpivirine. aNo prior exposure, Week 24: Q8W, n = 319; Q4W, 
n = 323; Week 48: Q8W, n = 319; Q4W, n = 324; prior exposure, 
Week 24: Q8W, n = 192; Q4W, n = 194; Week 48: Q8W, n = 192; 
Q4W, n = 194. Adjusted mean change from baseline calculated from 
an ANCOVA model including the following covariates: baseline 
score, sex at birth (female, male), age (< 50, ≥ 50  years), and race 
(white, non-white) for participants with no prior exposure; baseline 
score, sex at birth (female, male), age (< 50, ≥ 50 years), race (white, 
non-white), and prior exposure to CAB + RPV (1–24, > 24 weeks) for 
participants with prior exposure
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CAB+RPV LA Q8W CAB+RPV LA Q4W
Fig. 4  Adjusted mean change from baseline in HIVTSQs by visit for 
participants without prior CAB + RPV exposure (a) and with prior 
CAB + RPV exposure (b)a. ANCOVA analysis of covariance, CAB 
cabotegravir, CI confidence interval, HIVTSQs HIV Treatment Sat-
isfaction Questionnaire (status version), LA long-acting, Q4W every 
4  weeks, Q8W every 8  weeks, RPV rilpivirine. aNo prior exposure, 
Week 24: Q8W, n = 319; Q4W, n = 323; Week 48: Q8W, n = 319; 
Q4W, n = 323; prior exposure, Week 24: Q8W, n = 191; Q4W, 
n = 193; Week 48: Q8W, n = 191; Q4W, n = 194. Adjusted mean 
change from baseline calculated from an ANCOVA model including 
the following covariates: baseline score, sex at birth (female, male), 
age (< 50, ≥ 50  years), and race (white, non-white) for participants 
with no prior exposure; baseline score, sex at birth (female, male), 
age (< 50, ≥ 50 years), race (white, non-white), and prior exposure to 
CAB + RPV (1–24, > 24 weeks) for participants with prior exposure
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irrespective of prior CAB + RPV exposure (adjusted mean 
change [95% CI]: participants without prior exposure: Q8W 
28.9/33.0 [27.9–29.9]; Q4W 27.1/33.0 [26.1–28.0]; par-
ticipants with prior exposure: Q8W 28.9/33.0 [27.6–30.3]; 
Q4W 26.1/33.0 [24.7–27.4]). At Week 48, the scores rep-
resenting the change in satisfaction relative to the prior 
treatment significantly favored Q8W over Q4W, regard-
less of prior CAB + RPV exposure (adjusted difference 
[Q8W − Q4W] [95% CI]: participants without prior expo-
sure 1.9 [0.5–3.2], p = 0.008; participants with prior expo-
sure 2.9 [1.0–4.8], p = 0.004).
3.5  Preference
Among those participants in the Q8W arm with prior 
CAB + RPV exposure responding to the preference question 
at Week 48, 94% (n = 179/191) preferred CAB + RPV LA 
Q8W dosing versus Q4W (3%, n = 6/191) or daily oral dos-
ing (2%, n = 4/191) (Fig. 5a). Participants without prior 
CAB + RPV exposure who received CAB + RPV LA Q8W 
dosing with recorded responses to the preference question at 
Week 48 also preferred this regimen over daily oral dosing 
(98%, n = 300/306) (Fig. 5a). Participants in the Q4W group 
(no experience of Q8W dosing) responding to the prefer-
ence question at Week 48 preferred CAB + RPV LA Q4W 
dosing over daily oral dosing (94%, n = 468/497) (Fig. 5b). 
The most commonly cited reasons for long-acting preference 
were administration frequency and convenience, whereas 
the most common reasons supporting preference for daily 
oral dosing were the impact of side effects and conveni-
ence (electronic supplementary material Figure S4a, S4b, 
and S4c).
Fig. 5  Treatment preference 
at Week 48 in the Q8W arm 
(a) and Q4W arm (b). CAB 
cabotegravir, LA long-acting, 
Q4W every 4 weeks, Q8W 
every 8 weeks, RPV rilpiv-
irine, SOC standard of care. 
a306 participants responded 
to the preference question. 
b191 participants responded to 
the preference question. c497 
participants responded to the 
preference question. Figure 5a 
reprinted from The Lancet, 
Volume 396, Overton et al., 
Long-acting cabotegravir and 
rilpivirine dosed every 2 months 
in adults with HIV-1 infection 
(ATLAS-2M), 48-week results: 
a randomised, multicentre, 
open-label, phase 3b, non-infe-
riority study, Pages 1994–2005. 
Copyright (2020), with permis-
sion from Elsevier
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3.6  Reason for Switch
For participants originally randomized to the standard of 
care arm in ATLAS or coming from standard of care in the 
routine clinic, the reason most often selected for switching 
to long-acting therapy from standard of care was interest in 
new therapies (85%, n = 655/767) (electronic supplementary 
material Figure S2a). For participants originally randomized 
to the Q4W arm in ATLAS, the reason most often selected 
for continuing CAB + RPV LA treatment was the conveni-
ence associated with injectable therapy (87%, n = 220/253) 
(electronic supplementary material Figure S2b).
4  Discussion
The PRO data collected at Week 48 of the ATLAS-2M study 
demonstrate that both dosing regimens of CAB + RPV LA 
can improve and maintain treatment satisfaction and accept-
ance, supporting the therapeutic potential of the injectable 
regimen and highlighting participants’ preference for long-
acting therapy over daily oral dosing. These results com-
plement the high overall rates of virologic suppression 
and favorable safety and tolerability profiles observed for 
CAB + RPV LA Q8W and Q4W in ATLAS-2M [18]. The 
PRO analysis was stratified by prior CAB + RPV exposure to 
accommodate the difference in treatments assessed at base-
line. As such, participants without prior CAB + RPV expo-
sure were reporting their experience with daily oral therapy 
at baseline, whereas participants with prior CAB + RPV 
exposure were reporting their experience with the Q4W 
long-acting regimen they received during the ATLAS study.
Although ISRs were frequent during ATLAS-2M [18], 
particularly pain events, they seldom led to withdrawal and 
nearly all participants preferred the long-acting regimen 
to their previous oral therapy. The majority of participants 
reported high acceptability of pain and local reactions at 
early timepoints in the study, with acceptability increas-
ing with subsequent injections. These improvements are 
mirrored by the reduction in frequency of ISRs over time 
observed in the safety analysis of ATLAS-2M [18], pro-
viding evidence that ISRs associated with CAB + RPV LA 
become perceived as less burdensome over time by partici-
pants. Despite ISRs being more prevalent per visit with the 
Q8W regimen versus the Q4W regimen, although offset 
over time by less frequent dosing, similar improvements 
in acceptability of pain and local reactions were observed 
regardless of dosing regimen (Q8W vs. Q4W). Therefore, it 
could be argued that the increased volume of liquid delivered 
with the Q8W regimen does not impact the tolerability or 
acceptability of injections (Q8W 2 × 3 mL; Q4W 2 × 2 mL).
With respect to treatment satisfaction and acceptance, 
participants entering ATLAS-2M with only prior experience 
of daily oral therapy reported large improvements at Weeks 
24 and 48 across both long-acting groups. The magnitude 
of the improvements were consistent with the improve-
ments in satisfaction and acceptance observed in partici-
pants in the ATLAS and FLAIR phase 3 clinical studies, 
which for ATLAS was proven to meet the minimal clini-
cally important difference threshold [16, 17, 22]. For par-
ticipants entering ATLAS-2M having received CAB + RPV 
LA Q4W in ATLAS, treatment satisfaction and acceptance 
was high at baseline and maintained through Week 48 in 
both long-acting groups. Further, most participants transi-
tioning from ATLAS switched from the Q4W regimen and 
had therefore accumulated ≥ 96 weeks of CAB + RPV LA 
exposure by Week 48 of ATLAS-2M (65%, n = 253/391). 
These longer-term findings are consistent with the high 
participant satisfaction reported at Week 96 in FLAIR, 
and when taken together suggest that the benefits of long-
acting therapy can be sustained over ~ 2 years [38]. Over 
time, minor fluctuations are to be expected in treatment 
satisfaction and acceptance scores, both of which remained 
at high levels throughout the study. For participants with 
prior CAB + RPV exposure, the negative trend in treatment 
acceptance score was more pronounced for the Q4W arm. 
This could be attributable to some participants’ disappoint-
ment with receiving the same regimen they had received 
in ATLAS, missing the opportunity to initiate the less fre-
quent, potentially more desirable, Q8W dosing regimen. For 
treatment satisfaction scores, small decreases were observed 
between Weeks 24 and 48, irrespective of participants’ 
prior CAB + RPV exposure. For participants without prior 
CAB + RPV exposure and participants randomized to the 
Q8W regimen, this may be a consequence of inflated satis-
faction scores recorded at Week 24 due to the initial excite-
ment associated with receiving a novel therapeutic or being 
randomized to the less frequent dosing regimen.
For participants with prior CAB + RPV exposure, high 
values for both treatment acceptance and satisfaction 
(HIVTSQs) were maintained across treatment regimens; 
however, no significant differences were observed between 
Q8W and Q4W dosing. A significant difference favoring the 
Q8W regimen was only observed in treatment satisfaction 
(HIVTSQs) for participants without prior CAB + RPV expo-
sure. This can be partially attributed to the ceiling effects 
observed with the use of the ACCEPT and HIVTSQs instru-
ments, which mean the high baseline values for participants 
with prior CAB + RPV exposure do not permit the full mag-
nitude of treatment effects to become apparent. With the 
use of HIVTSQc, developed to account for ceiling effects, 
the change in satisfaction relative to prior treatment scores 
significantly favored Q8W over Q4W at Week 48, irrespec-
tive of prior exposure.
Preference questionnaires revealed that almost all partici-
pants with experience of both the Q8W and Q4W regimens 
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preferred Q8W dosing, the reasons for which highlight the 
perceived value of reduced dosing frequencies and greater 
convenience for participants. In addition to the participant-
reported reasons for preference, the Q8W regimen has been 
observed to have comparable efficacy and tolerability to 
the Q4W regimen [18]. Further, the Q8W regimen offers 
fewer opportunities for missed injections and requires half 
the number of clinical visits per year. Whilst previous stud-
ies have reported strong preferences for the long-acting 
regimen over daily oral antiretroviral therapy [16, 17, 20, 
22], ATLAS-2M represents the first phase 3 clinical study 
to report participant preference for Q8W dosing over Q4W 
dosing, consistent with the greater increases in satisfaction 
reported in Q8W arm participants compared with those in 
the Q4W arm. The Q8W regimen has several potential real-
world advantages over Q4W dosing, as it facilitates fewer 
clinical interventions as well as reducing the total number 
of treatments/visits to six per year (excluding first loading 
dose).
Overall, the findings of these analyses provide robust evi-
dence supporting the benefits of long-acting therapy outside 
of the clinically focused parameters of efficacy and safety, 
prioritizing an evaluation of the patient’s experience and 
preferences. This sentiment is in keeping with the general 
trend towards a more patient-centered focus in the care of 
people living with HIV-1. Patient satisfaction may contrib-
ute to individual improvements in adherence, which in turn 
translates to better management of HIV [23]. Increasing 
patient satisfaction is also vital to improving overall quality 
of life for people living with HIV-1, a metric of ever-increas-
ing importance as the efficacy, tolerability, and accessibility 
of HIV therapeutics continue to improve [1]. The results col-
lected at Week 48 of the ATLAS-2M study are illustrative of 
the therapeutic potential of CAB + RPV LA, not only as an 
efficacious and well-tolerated maintenance regimen, but also 
as a regimen with the potential to facilitate improvements in 
adherence and a person’s overall quality of life. The trans-
lation of long-acting therapies into everyday widespread 
clinical practice warrants comprehensive investigation and 
is undergoing evaluation [39].
4.1  Limitations
The present study has several limitations. Although ATLAS-
2M met its enrollment target of 25% female participants 
(sex at birth) and also included > 25% of participants 
aged ≥ 50 years, the enrolled population did not include large 
proportions of other under-represented groups, including 
people from racial and ethnic minority groups, transgender 
individuals, and individuals with historic suboptimal adher-
ence [18]. In addition, the enrolled population may reflect a 
select population of people living with HIV-1 interested in 
long-acting therapies. Further research, including real-world 
evidence, is ongoing or planned to evaluate CAB + RPV LA 
in different patient demographics and describe use in broader 
populations of people living with HIV-1. For example, the 
ongoing LATITUDE study (NCT03635788) is investigating 
CAB + RPV LA in a population with historic suboptimal 
adherence [40]. In addition, studies that directly compare 
CAB + RPV LA Q8W with contemporary standard of care 
antiretroviral regimens are warranted and have been planned, 
such as the upcoming SOLAR (NCT04542070) study, which 
will evaluate CAB + RPV LA dosed every 2 months com-
pared with a bictegravir/emtricitabine/tenofovir alafena-
mide–based oral daily regimen [41]. A small proportion 
of study participants (14%; n = 147/1020 [respondents]) 
answered “cost of alternative options/current HIV drug or 
to continue receiving free study drug” as their reason for 
switching to/continuing long-acting therapy. This result 
could have inadvertently revealed a source of unconscious 
bias, which may have augmented some PRO item scores. 
The absence of a therapeutic alternative for participants due 
to economic constraints may also qualify as undue influence. 
However, participants provided written informed consent, 
which was approved by national, regional, or investigational 
center ethics committees or institutional review board, in 
accordance with The International Conference on Harmo-
nisation Good Clinical Practice Guideline and applicable 
country-specific requirements.
5  Conclusions
Irrespective of dosing regimen, CAB + RPV LA was asso-
ciated with large increases in treatment satisfaction and 
high acceptance of ISRs for those naive to CAB + RPV. For 
those with prior experience of the intramuscular regimen, 
CAB + RPV LA maintained high levels of satisfaction and 
acceptance. Most participants preferred Q8W and Q4W dos-
ing over daily oral dosing, with Q8W also preferred over 
Q4W dosing. The PRO data presented here, along with 
the high rates of virologic suppression, low rates of viro-
logic failure, and favorable safety and tolerability profiles 
presented in the primary analysis, support the therapeutic 
potential of monthly or every 2 months CAB + RPV LA and 
highlight participants’ preference for long-acting therapy 
over daily oral dosing.
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